Abstract: Objective To summarize the clinical characteristics and treatment effect of hepatoblastoma (HB) in Beijing Children's Hospital in the past ten years, and further to provide the basis for reasonable diagnosis and treatment strategy to reduce the side effects and improve the event-free survival. Methods The patients who received multidisciplinary medical therapy, including surgery, radiotherapy and chemotherapy, and followed up regularly were enrolled into the group. The chemotherapy includes regimen A (vincristine + cisplatin + fluorouracil) and regimen B (cisplatin + doxorubicin). We recorded the age, sex, course of disease, initial serum alpha fetal protein(AFP), clinical stage, pathological type, treatment and treatment effect of all the patients. The cut-off data of follow-up was November 30, 2018. Results In total 51 cases admitted in our hospital, 42 cases were admitted into the research group (six cases were treated in other hospitals, three cases died because of the tumor rupture before treatment). According to the cases of medical recorder in the group, the median age was 19 months (2-102 months); 1 case in stage Ⅱ, 34 cases in stage Ⅲ, and 7 cases in stageⅣ. The value of AFP was in the range of 31.6-2 200 000 μg/L(median data was 192 274.5 μg/L).The median follow-up was 36 months (6-115 months) in 39 cases, and the 5-year event-free survival (EFS) was 74.72%. After the chemotherapy, the whole blood cells decreased insignificantly. Neither severe infection nor cardio toxicity and hearing impairment occurred during chemotherapy. Conclusion Comprehensive treatment and management of surgery combined with chemotherapy is the main treatment for children with HB. The dosage of doxorubicin and cisplatin in the current regimen is tolerable, with fewer side effects, and the 5-year EFS is better. Long-term follow-up of these children is needed in the future.

Key words: hepatoblastoma, child, curative effect, multidisciplinary treatment